Concord Biotech IPO: From key dates to price band, all you need to know

livemint.com:

₹705 to ₹741 per equity share of face value of ₹1 each. Concord Biotech IPO lot size is 20 equity shares and in multiples of 20 equity shares thereafter. Rakesh Jhunjhunwala backed Concord Biotech IPO consists of a pure offer-for-sale by Helix Investment Holdings Pte Ltd.

of up to 20.93 million shares. The issue offer is priced at ₹1,550 crore on the upper band, and the firm is worth ₹7,752 crore. 20% of the company is owned by Helix Investment Holdings Pte Ltd, which is backed by Quadria Capital Fund LP, an Asian private equity fund with a focus on healthcare.

Rakesh Jhunjhunwala owned 24.09% of the company through his asset management company RARE Enterprises (via RARE Trusts). In 2004, Rekha and Rakesh Jhunjhunwala made an investment in Concord Biotech. The book-running lead managers (BRLM) for the Concord Biotech IPO offer are Kotak Mahindra Capital Company Ltd, Citigroup Global Markets India Private Ltd, and Jefferies India Private Ltd, while Link Intime India Private Ltd is the registrar.

Concord Biotech IPO has reserved not more than 50% of the shares in the public issue for Qualified Institutional Buyers (QIB), not less than 15% for Non Institutional Investors (NII), and not less than 35% of the offer is reserved for Retail Investors. Concord Biotech IPO date: Concord Biotech IPO's basis of allotment of shares will be finalised on Friday, August 11 and the company will initiate refunds on Monday, August 14, while the shares will be credited to the demat account of allottees on Thursday, 17 August. Concord Biotech IPO shares are likely to be listed on BSE and NSE on Friday, August 18.